Identification of Mitophagy-associated Proteins Profile As Potential Plasma Biomarkers of Idiopathic Parkinson's Disease

Overview

Journal CNS Neurosci Ther

Specialties Neurology
Pharmacology

Date 2023 Nov 22

PMID 37990436

Authors

Shuangjie Qian

Haijun He

Xi Xiong

Ruixue Ai

Wenwen Wang

Huimin Zhu

Qianqian Ye

Shuoting Zhou

Hilde Nilsen

Chenglong Xie

Affiliations

Soon will be listed here.

Abstract

Background: Despite extensive work to identify diagnostic plasma markers for Parkinson's disease (PD), there are still no accepted and validated surrogate biomarkers. Mitophagy-associated proteins (MAPs), including PTEN-induced putative kinase 1 (PINK1), Parkin, phosphoglycerate mutase 5 (PGAM5), BCL2 interacting protein 3 (BNIP3), and phosphorylated-TBK1 (p-TBK1), are, to our best knowledge, not well studied as a panel of biomarkers of neurodegeneration in PD.

Methods: The study population comprised 116 age-matched controls (HC), 179 PD patients, alongside and 90 PD syndromes (PDs) divided between two cohorts: (i) the modeling cohort (cohort 1), including 150 PD, 97 HC, and 80 PDs; and (ii) the validated cohort (cohort 2), including 29 PD, 19 HC, and 10 PDs.

Results: MAPs are elevated in the plasma of PD patients. PINK1, Parkin, and PGAM5 displayed the top three measurable increase trends in amplitude compared to BNIP3 and p-TBK1. Moreover, the area under the curve (AUC) values of PINK1, PGAM5, and Parkin were ranked the top three MAP candidates in diagnosis accuracy for PD from HC, but the MAPs make it hard to differentiate PD from PDs. In addition, there are higher plasma PINK1-Parkin levels and prominent diagnostic accuracy in A-synuclein (+) subjects than in A-synuclein (-) subjects.

Conclusions: These results uncover that plasma MAPs (PINK1, Parkin, and PGAM5) may be potentially useful diagnostic biomarkers for PD diagnosis. Studies on larger cohorts would be required to test whether elevated plasma MAP levels are related to PD risk or prognosis.

Citing Articles

Parkin characteristics and blood biomarkers of Parkinson's disease in WPBLC study.

He H, Xiong X, Zheng Y, Hou J, Jiang T, Quan W Front Aging Neurosci. 2025; 17:1511272.

PMID: 40078640 PMC: 11897490. DOI: 10.3389/fnagi.2025.1511272.

Mitochondrial DNA leakage: underlying mechanisms and therapeutic implications in neurological disorders.

Zhang G, Wei H, Zhao A, Yan X, Zhang X, Gan J J Neuroinflammation. 2025; 22(1):34.

PMID: 39920753 PMC: 11806845. DOI: 10.1186/s12974-025-03363-0.

5-Methoxytryptophan Alleviates Lipopolysaccharide-Induced Acute Kidney Injury by Regulating Nrf2-Mediated Mitophagy.

Sun X, Wang H, Liu Y, Yang Y, Wang Y, Liu Y J Inflamm Res. 2024; 17:9857-9873.

PMID: 39618934 PMC: 11608550. DOI: 10.2147/JIR.S474040.

Alterations of human CSF and serum-based mitophagy biomarkers in the continuum of Alzheimer disease.

Veverova K, Laczo J, Katonova A, Horakova H, Matuskova V, Angelucci F Autophagy. 2024; 20(8):1868-1878.

PMID: 38695174 PMC: 11262225. DOI: 10.1080/15548627.2024.2340408.

Identification of mitophagy-associated proteins profile as potential plasma biomarkers of idiopathic Parkinson's disease.

Qian S, He H, Xiong X, Ai R, Wang W, Zhu H CNS Neurosci Ther. 2023; 30(4):e14532.

PMID: 37990436 PMC: 11056850. DOI: 10.1111/cns.14532.

References

Gegg M, Schapira A . PINK1-parkin-dependent mitophagy involves ubiquitination of mitofusins 1 and 2: Implications for Parkinson disease pathogenesis. Autophagy. 2010; 7(2):243-5. PMC: 4196638. DOI: 10.4161/auto.7.2.14332. View

Qian S, He H, Xiong X, Ai R, Wang W, Zhu H . Identification of mitophagy-associated proteins profile as potential plasma biomarkers of idiopathic Parkinson's disease. CNS Neurosci Ther. 2023; 30(4):e14532. PMC: 11056850. DOI: 10.1111/cns.14532. View

Villa E, Marchetti S, Ricci J . No Parkin Zone: Mitophagy without Parkin. Trends Cell Biol. 2018; 28(11):882-895. DOI: 10.1016/j.tcb.2018.07.004. View

Vrieze S . Model selection and psychological theory: a discussion of the differences between the Akaike information criterion (AIC) and the Bayesian information criterion (BIC). Psychol Methods. 2012; 17(2):228-43. PMC: 3366160. DOI: 10.1037/a0027127. View

Lin Q, Li S, Jiang N, Jin H, Shao X, Zhu X . Inhibiting NLRP3 inflammasome attenuates apoptosis in contrast-induced acute kidney injury through the upregulation of HIF1A and BNIP3-mediated mitophagy. Autophagy. 2020; 17(10):2975-2990. PMC: 8525960. DOI: 10.1080/15548627.2020.1848971. View

Heo J, Ordureau A, Swarup S, Paulo J, Shen K, Sabatini D . RAB7A phosphorylation by TBK1 promotes mitophagy via the PINK-PARKIN pathway. Sci Adv. 2019; 4(11):eaav0443. PMC: 6314648. DOI: 10.1126/sciadv.aav0443. View

Moore A, Holzbaur E . Dynamic recruitment and activation of ALS-associated TBK1 with its target optineurin are required for efficient mitophagy. Proc Natl Acad Sci U S A. 2016; 113(24):E3349-58. PMC: 4914160. DOI: 10.1073/pnas.1523810113. View

Desquilbet L, Mariotti F . Dose-response analyses using restricted cubic spline functions in public health research. Stat Med. 2010; 29(9):1037-57. DOI: 10.1002/sim.3841. View

Armstrong M, Okun M . Diagnosis and Treatment of Parkinson Disease: A Review. JAMA. 2020; 323(6):548-560. DOI: 10.1001/jama.2019.22360. View

10.

Goedert M, Spillantini M, Del Tredici K, Braak H . 100 years of Lewy pathology. Nat Rev Neurol. 2012; 9(1):13-24. DOI: 10.1038/nrneurol.2012.242. View

11.

Foulds P, Mitchell J, Parker A, Turner R, Green G, Diggle P . Phosphorylated α-synuclein can be detected in blood plasma and is potentially a useful biomarker for Parkinson's disease. FASEB J. 2011; 25(12):4127-37. DOI: 10.1096/fj.10-179192. View

12.

Stuendl A, Kraus T, Chatterjee M, Zapke B, Sadowski B, Moebius W . α-Synuclein in Plasma-Derived Extracellular Vesicles Is a Potential Biomarker of Parkinson's Disease. Mov Disord. 2021; 36(11):2508-2518. DOI: 10.1002/mds.28639. View

13.

Li S, Wing Y, Lam S, Zhang J, Yu M, Ho C . Validation of a new REM sleep behavior disorder questionnaire (RBDQ-HK). Sleep Med. 2009; 11(1):43-8. DOI: 10.1016/j.sleep.2009.06.008. View

14.

Wang Z, Becker K, Donadio V, Siedlak S, Yuan J, Rezaee M . Skin α-Synuclein Aggregation Seeding Activity as a Novel Biomarker for Parkinson Disease. JAMA Neurol. 2020; . PMC: 7522783. DOI: 10.1001/jamaneurol.2020.3311. View

15.

Bengoa-Vergniory N, Roberts R, Wade-Martins R, Alegre-Abarrategui J . Alpha-synuclein oligomers: a new hope. Acta Neuropathol. 2017; 134(6):819-838. PMC: 5663814. DOI: 10.1007/s00401-017-1755-1. View

16.

Walker Z, Gandolfo F, Orini S, Garibotto V, Agosta F, Arbizu J . Clinical utility of FDG PET in Parkinson's disease and atypical parkinsonism associated with dementia. Eur J Nucl Med Mol Imaging. 2018; 45(9):1534-1545. PMC: 6061481. DOI: 10.1007/s00259-018-4031-2. View

17.

Sliter D, Martinez J, Hao L, Chen X, Sun N, Fischer T . Parkin and PINK1 mitigate STING-induced inflammation. Nature. 2018; 561(7722):258-262. PMC: 7362342. DOI: 10.1038/s41586-018-0448-9. View

18.

HOEHN M, Yahr M . Parkinsonism: onset, progression and mortality. Neurology. 1967; 17(5):427-42. DOI: 10.1212/wnl.17.5.427. View

19.

Kuhle J, Barro C, Andreasson U, Derfuss T, Lindberg R, Sandelius A . Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa. Clin Chem Lab Med. 2016; 54(10):1655-61. DOI: 10.1515/cclm-2015-1195. View

20.

Shaltouki A, Hsieh C, Kim M, Wang X . Alpha-synuclein delays mitophagy and targeting Miro rescues neuron loss in Parkinson's models. Acta Neuropathol. 2018; 136(4):607-620. PMC: 6123262. DOI: 10.1007/s00401-018-1873-4. View